The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

被引：73

作者：

Lacouture, M. E.

Lai, S. E.

机构：

[1] Northwestern Univ, Canc Skin Care Program, Chicago, IL 60611 USA

[2] Northwestern Univ, SERIES Clin, Dept Dermatol, Chicago, IL 60611 USA

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2006年 / 155卷 / 04期

关键词：

D O I：

10.1111/j.1365-2133.2006.07452.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：852 / 854

页数：4

共 10 条

[1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[2] Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 [J].

Busam, KJ ;

Capodieci, P ;

Motzer, R ;

Kiehn, T ;

Phelan, D ;

Halpern, AC .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) :1169-1176

[3] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[4]

Lacouture Mario E, 2006, J Support Oncol, V4, P236

[5] EXPRESSION OF A DOMINANT-NEGATIVE MUTANT OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN THE EPIDERMIS OF TRANSGENIC MICE ELICITS STRIKING ALTERATIONS IN HAIR FOLLICLE DEVELOPMENT AND SKIN-STRUCTURE [J].

MURILLAS, R ;

LARCHER, F ;

CONTI, CJ ;

SANTOS, M ;

ULLRICH, A ;

JORCANO, JL .

EMBO JOURNAL, 1995, 14 (21) :5216-5223

[6] Cutaneous adverse effects with HER1/EGFR-targeted agents:: Is there a silver lining? [J].

Peréz-Soler, R ;

Saltz, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5235-5246

[7] Clinical heterogeneity of drug hypersensitivity [J].

Roujeau, JC .

TOXICOLOGY, 2005, 209 (02) :123-129

[8] Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors [J].

Segaert, S ;

Van Cutsem, E .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1425-1433

[9] Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab [J].

Suh, KY ;

Kindler, HL ;

Medenica, M ;

Lacouture, M .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01) :191-192

[10] Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor [J].

van Doorn, R ;

Kirtschig, G ;

Scheffer, E ;

Stoof, TJ ;

Giaccone, G .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) :598-601

← 1 →